Figure 4. Vaccination with HSV-2 ΔgD^−/+gD−1 protects mice infected with HSV-2 and HSV-1 in a skin scarification model.

Mice were subcutaneously primed and boosted 3 weeks apart either with HSV-2 ΔgD^−/+gD−1, Control VD60 cell lysate or PBS. 3 weeks later, mice were depilated and challenged in the flank skin with PBS (mock), (A) 5 × 10⁴ pfu HSV-2(4674) or (B), 1 × 10⁷ pfu HSV-1(17). Representative images are shown. (C) Skin disease scores for HSV-2(4674)-challenged mice at days 3–11. (D) Viral titers from biopsies of skin or neural tissue obtained on day 6–7 (Control mice) and day 14 (HSV-2 ΔgD^−/+gD−1-vaccinated mice) (n = 5 mice per group, lines indicate means). (E) HSV-2 DNA (qPCR, U_S6 gene) in skin biopsies and neural tissue of Control mice (day 6–7) and HSV-2 ΔgD^−/+gD−1-vaccinated mice (day 14) challenged with virus (5 mice per group, lines indicate means). Statistical significance was measured by two-way ANOVA with Sidak's multiple comparisons test (D and E); ***p < 0.001, ΔgD^−/+gD−1-vaccinated group vs control group. HSV-2 ΔgD^−/+gD−1 is abbreviated as ΔgD.

DOI: http://dx.doi.org/10.7554/eLife.06054.007

Figure 4—figure supplement 1. Vaccination with HSV-2 ΔgD^−/+gD−1 protects mice infected with HSV-1 in a skin scarification model.

Mice were subcutaneously primed and boosted 3 weeks apart either with HSV-2 ΔgD^−/+gD−1 or Control VD60 cell lysate. 3 weeks later, mice were depilated and challenged in the flank skin with1 × 10⁷ pfu HSV-1(17). Skin disease scores shown for challenged mice at days 3–11. Viral titers from biopsies of skin obtained on day 7–8 (Control mice) and day 14 (HSV-2 ΔgD^−/+gD−1-vaccinated mice) (n = 5 mice per group, lines indicate means). Statistical significance was measured by unpaired t-test.

DOI: http://dx.doi.org/10.7554/eLife.06054.008